-
1 Comment
Sequana Medical NV is currently in a long term downtrend where the price is trading 1.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 121.6.
Sequana Medical NV's total revenue rose by 6.6% to $595K since the same quarter in the previous year.
Its net income has dropped by 24.5% to $-10M since the same quarter in the previous year.
Finally, its free cash flow fell by 13.1% to $-4M since the same quarter in the previous year.
Based on the above factors, Sequana Medical NV gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Exchange | BR |
| CurrencyCode | EUR |
| ISIN | BE0974340722 |
| Industry | Medical Devices |
| Market Cap | 54M |
|---|---|
| PE Ratio | None |
| Target Price | 3.9667 |
| Beta | -0.03 |
| Dividend Yield | None |
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SEQUA.BR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
